Bright Outlook for Nektar Therapeutics (NKTR) Hinges on Positive Trial Results
Michigan-based investment advisor Cedar Grove Capital Management recently released its first quarter 2026 investor letter. A copy of the letter can be downloaded here.
Nektar Therapeutics (NKTR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 202,500 | $14,569,875 | 1.44% | ||
| 2. | Bronte Capital John Hempton | 198,256 | $14,264,519 | 1.41% | |
| 3. | Iridian Asset Management David Cohen And Harold Levy | 31,320 | $2,253,474 | +222% | 0.91% |
| 4. | Bayforest Capital Theodoros Tsagaris | 2,538 | $182,609 | -1% | 0.2% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.28 | 15,000 | $259,200.00 | 107,668 | 2019-09-05 | Filing | |
| $59.80 | 1,400 | $83,720.00 | 177,000 | 2018-06-06 | Filing | |
| $59.07 | 2,000 | $118,140.00 | 175,600 | 2018-06-06 | Filing | |
| $55.22 | 1,600 | $88,352.00 | 173,600 | 2018-06-05 | Filing | |
| $17.95 | 35,000 | $628,250.00 | 133,000 | 2017-08-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.00 | 180 | $13,140.00 | 21,174 | 2026-02-18 | Filing | |
| $73.00 | 423 | $30,879.00 | 75,489 | 2026-02-18 | Filing | |
| $35.67 | 3,867 | $137,935.89 | 21,354 | 2026-01-20 | Filing | |
| $54.28 | 1,157 | $62,801.96 | 18,971 | 2025-11-25 | Filing | |
| $54.28 | 630 | $34,196.40 | 21,585 | 2025-11-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 89,527 | $6,441,468 | 1.16% | |
| 2. | 26,545 | $1,909,913 | 0.04% | |
| 3. | 5,200 | $374,140 | 0% | |
| 4. | 5,000 | $359,750 | 0.27% | |
| 5. | 4,000 | $287,800 | 0.02% |
News See All
Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript
Operator: Hello, and thank you for standing by. Welcome to the Nektar Therapeutics fourth quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode.
Nektar Therapeutics (NKTR): A Bull Case Theory
We came across a bullish thesis on Nektar Therapeutics on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on NKTR.
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR)
The trial narrowly missed its primary endpoint; however, Oppenheimer highlighted that omitting four patients with eligibility violations yielded nominal statistical significance.
12 Best Multibagger Stocks to Buy Heading into 2026
As we head into 2026, the biggest question market participants are asking is whether the strong momentum this year can carry over into next year.
Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now?
Nektar Therapeutics (NASDAQ:NKTR) is among the hottest SMID-cap stocks so far in 2025.
10 Hottest SMID-Cap Stocks So Far In 2025
SMID-caps, or Small- and mid-cap stocks, are often overlooked segments of the market.
Nektar Therapeutics (NASDAQ:NKTR) Q3 2025 Earnings Call Transcript
Operator: Hello, and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2025 Financial Results Conference Call.
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation
Nektar Therapeutics (NASDAQ:NKTR) is one of the hot stocks to buy with huge upside potential.
12 Hot Stocks to Buy with Huge Upside Potential
On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.
Hedge Fund Resource Center